Travere Therapeutics (TVTX) Projected to Post Quarterly Earnings on Thursday

Travere Therapeutics (NASDAQ:TVTX) is projected to release its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect the company to announce earnings of ($0.0409) per share and revenue of $198.32 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 2, 2026 at 4:30 PM ET.

Travere Therapeutics (NASDAQ:TVTX) last issued its earnings results on Tuesday, August 4th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.03. The firm had revenue of $169.58 million during the quarter, compared to the consensus estimate of $157.27 million. Travere Therapeutics had a negative return on equity of 55.15% and a negative net margin of 7.35%. The business’s quarterly revenue was up 48.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.13 earnings per share. On average, analysts expect Travere Therapeutics to post ($0.92) EPS for the current fiscal year and $2.49 EPS for the next fiscal year.

Travere Therapeutics Stock Down 0.2%

TVTX stock opened at $49.97 on Tuesday. The stock has a market capitalization of $4.71 billion, a P/E ratio of -108.63 and a beta of 1.13. The company has a current ratio of 4.05, a quick ratio of 3.99 and a debt-to-equity ratio of 24.58. Travere Therapeutics has a 12 month low of $22.59 and a 12 month high of $68.73. The firm has a 50-day moving average price of $60.16 and a 200-day moving average price of $46.15.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on TVTX. TD Cowen upped their price objective on shares of Travere Therapeutics from $60.00 to $75.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Weiss Ratings restated a “sell (e+)” rating on shares of Travere Therapeutics in a research report on Friday, September 18th. Zacks Research lowered shares of Travere Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 20th. Evercore set a $78.00 target price on shares of Travere Therapeutics in a research note on Monday, August 10th. Finally, Citigroup boosted their target price on shares of Travere Therapeutics from $70.00 to $85.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Ten research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Travere Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $69.50.

Insider Buying and Selling at Travere Therapeutics

In other Travere Therapeutics news, EVP Peter Heerma sold 8,282 shares of the company’s stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $65.07, for a total value of $538,909.74. Following the completion of the transaction, the executive vice president directly owned 117,066 shares in the company, valued at approximately $7,617,484.62. This represents a 6.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider William E. Rote sold 112,850 shares of the firm’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $63.33, for a total transaction of $7,146,790.50. Following the transaction, the insider directly owned 98,197 shares of the company’s stock, valued at $6,218,816.01. The trade was a 53.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,294,029 shares of company stock worth $79,454,261 over the last quarter. Insiders own 4.44% of the company’s stock.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases, with an emphasis on serious kidney conditions. The company’s work centers on addressing diseases with limited treatment options and improving outcomes for patients with progressive renal disorders.

Travere’s lead commercial product is FILSPARI (sparsentan), an oral treatment for adults with primary immunoglobulin A nephropathy (IgA nephropathy) who are at risk of disease progression.